Incidence of ocular hemorrhages in anticoagulated patients receiving repeated intravitreal injections.
Meyer
Carsten H
CH
Eter
Nicole
N
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D052157:Aptamers, Nucleotide / Q000009:adverse effects / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology; D004359:Drug Therapy, Combination; D005130:Eye Hemorrhage / Q000139:chemically induced / Q000453:epidemiology*; D006801:Humans; D015994:Incidence; D007267:Injections; D008268:Macular Degeneration / Q000150:complications; D012307:Risk Factors; D042461:Vascular Endothelial Growth Factor A; D014822:Vitreous Body; D014859:Warfarin / Q000008:administration & dosage* / Q000009:adverse effects
D020533:Angiogenesis Inhibitors; D000925:Anticoagulants; D052157:Aptamers, Nucleotide; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D014859:Warfarin; D001241:Aspirin